45P Circular RNA NCAPG promotes breast cancer metastasis through acting as the sponge of miR-200s (English)
- New search for: He, Y.
- New search for: Tang, J.
- New search for: He, Y.
- New search for: Tang, J.
In:
ANNALS OF ONCOLOGY
;
29
;
N/A
;
2018
-
ISSN:
- Article (Journal) / Print
-
Title:45P Circular RNA NCAPG promotes breast cancer metastasis through acting as the sponge of miR-200s
-
Contributors:
-
Published in:ANNALS OF ONCOLOGY ; 29 ; N/A
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2018-01-01
-
Size:N/A
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 29
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapyBaracos, V. E. / Arribas, L. et al. | 2018
- 7
-
Liquid biopsy: another tool towards tailored therapy in colorectal cancerTarazona, N. / Cervantes, A. et al. | 2018
- 8
-
Monitoring resistance through liquid biopsyParikh, A. R. / Corcoran, R. B. et al. | 2018
- 10
-
Muscle protein anabolism in advanced cancer patients: response to protein and amino acids support, and to physical activityAntoun, S. / Raynard, B. et al. | 2018
- 11
-
Will liquid biopsies become our fluid transition to personalized immunotherapy?Wauters, E. / Vansteenkiste, J. et al. | 2018
- 13
-
Not only tumor but also therapy heterogeneityGarattini, S. / Nerini, I. F. / D’Incalci, M. et al. | 2018
- 18
-
Insulin resistance and body composition in cancer patientsDev, R. / Bruera, E. / Dalal, S. et al. | 2018
- 18
-
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAnessTutt, A. et al. | 2018
- 21
-
Novel treatment options for refractory Germ Cell Tumours: back to the bench!Kollmannsberger, C. / Nappi, L. / Nichols, C. et al. | 2018
- 23
-
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweetArmstrong, A. J. / Antonarakis, E. S. / Taplin, M.-E. / Kelly, W. K. / Beltran, H. / Fizazi, K. / Dahut, W. L. / Shore, N. / Slovin, S. / George, D. et al. | 2018
- 25
-
Biosimilars in oncology: much ado about nothing?Aapro, M. et al. | 2018
- 26
-
BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patientsPaluch-Shimon, S. / Peccatori, F. A. et al. | 2018
- 27
-
Struggling with nutrition in patients with advanced cancer: nutrition and nourishment—focusing on metabolism and supportive careArends, J. et al. | 2018
- 28
-
Annals of Oncology: factors for making a real impactAndré, F. et al. | 2018
- 30
-
The European Society for Medical Oncology (ESMO) Precision Medicine GlossaryYates, L. R. / Seoane, J. / Le Tourneau, C. / Siu, L. L. / Marais, R. / Michiels, S. / Soria, J. C. / Campbell, P. / Normanno, N. / Scarpa, A. et al. | 2018
- 36
-
European Society for Medical Oncology (ESMO) position paper on supportive and palliative careJordan, K. / Aapro, M. / Kaasa, S. / Ripamonti, C. I. / Scotté, F. / Strasser, F. / Young, A. / Bruera, E. / Herrstedt, J. / Keefe, D. et al. | 2018
- 44
-
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOSYoshino, T. / Arnold, D. / Taniguchi, H. / Pentheroudakis, G. / Yamazaki, K. / Xu, R.-H. / Kim, T. W. / Ismail, F. / Tan, I. B. / Yeh, K.-H. et al. | 2018
- 71
-
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapyRotte, A. / Jin, J. Y. / Lemaire, V. et al. | 2018
- 84
-
Comprehensive analysis of the clinical immuno-oncology landscapeTang, J. / Shalabi, A. / Hubbard-Lucey, V. M. et al. | 2018
- 92
-
From hepatitis C virus infection to B-cell lymphomaCouronné, L. / Bachy, E. / Roulland, S. / Nadel, B. / Davi, F. / Armand, M. / Canioni, D. / Michot, J. M. / Visco, C. / Arcaini, L. et al. | 2018
- 101
-
The use of antidepressants in oncology: a review and practical tips for oncologistsGrassi, L. / Nanni, M. G. / Rodin, G. / Li, M. / Caruso, R. et al. | 2018
- 112
-
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trialNormanno, N. / Abate, R. E. / Lambiase, M. / Forgione, L. / Cardone, C. / Iannaccone, A. / Sacco, A. / Rachiglio, A. M. / Martinelli, E. / Rizzi, D. et al. | 2018
- 119
-
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancerSiena, S. / Sartore-Bianchi, A. / Garcia-Carbonero, R. / Karthaus, M. / Smith, D. / Tabernero, J. / Van Cutsem, E. / Guan, X. / Boedigheimer, M. / Ang, A. et al. | 2018
- 127
-
A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancerBauer, L. / Hapfelmeier, A. / Blank, S. / Reiche, M. / Slotta-Huspenina, J. / Jesinghaus, M. / Novotny, A. / Schmidt, T. / Grosser, B. / Kohlruss, M. et al. | 2018
- 133
-
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study resultsAparicio, T. / Bouché, O. / Taieb, J. / Maillard, E. / Kirscher, S. / Etienne, P.-L. / Faroux, R. / Akouz, F. K. / El Hajbi, F. / Locher, C. et al. | 2018
- 139
-
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancerOverman, M. J. / Adam, L. / Raghav, K. / Wang, J. / Kee, B. / Fogelman, D. / Eng, C. / Vilar, E. / Shroff, R. / Dasari, A. et al. | 2018
- 145
-
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancerFribbens, C. / Garcia Murillas, I. / Beaney, M. / Hrebien, S. / O’Leary, B. / Kilburn, L. / Howarth, K. / Epstein, M. / Green, E. / Rosenfeld, N. et al. | 2018
- 154
-
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II studyHan, H. S. / Diéras, V. / Robson, M. / Palácová, M. / Marcom, P. K. / Jager, A. / Bondarenko, I. / Citrin, D. / Campone, M. / Telli, M. L. et al. | 2018
- 162
-
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancerCriscitiello, C. / Bayar, M. A. / Curigliano, G. / Symmans, F. W. / Desmedt, C. / Bonnefoi, H. / Sinn, B. / Pruneri, G. / Vicier, C. / Pierga, J. Y. et al. | 2018
- 170
-
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockadeNuciforo, P. / Pascual, T. / Cortés, J. / Llombart-Cussac, A. / Fasani, R. / Paré, L. / Oliveira, M. / Galvan, P. / Martínez, N. / Bermejo, B. et al. | 2018
- 178
-
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC triaMöbus, V. / Jackisch, C. / Lück, H. J. / du Bois, A. / Thomssen, C. / Kuhn, W. / Nitz, U. / Schneeweiss, A. / Huober, J. / Harbeck, N. et al. | 2018
- 186
-
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsNabieva, N. / Kellner, S. / Fehm, T. / Häberle, L. / de Waal, J. / Rezai, M. / Baier, B. / Baake, G. / Kolberg, H.-C. / Guggenberger, M. et al. | 2018
- 193
-
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancerIlié, M. / Szafer-Glusman, E. / Hofman, V. / Chamorey, E. / Lalvée, S. / Selva, E. / Leroy, S. / Marquette, C.-H. / Kowanetz, M. / Hedge, P. et al. | 2018
- 200
-
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape ProjectKerr, K. M. / Dafni, U. / Schulze, K. / Thunnissen, E. / Bubendorf, L. / Hager, H. / Finn, S. / Biernat, W. / Vliegen, L. / Losa, J. H. et al. | 2018
- 209
-
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206Adra, N. / Einhorn, L. H. / Althouse, S. K. / Ammakkanavar, N. R. / Musapatika, D. / Albany, C. / Vaughn, D. / Hanna, N. H. et al. | 2018
- 215
-
Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapyJain, S. / Lyons, C. A. / Walker, S. M. / McQuaid, S. / Hynes, S. O. / Mitchell, D. M. / Pang, B. / Logan, G. E. / McCavigan, A. M. / O’Rourke, D. et al. | 2018
- 223
-
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patientsCastillo, J. / Bernard, V. / San Lucas, F. A. / Allenson, K. / Capello, M. / Kim, D. U. / Gascoyne, P. / Mulu, F. C. / Stephens, B. M. / Huang, J. et al. | 2018
- 230
-
Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practiceMoorcraft, S. Y. / de Castro, D. G. / Cunningham, D. / Jones, T. / Walker, B. A. / Peckitt, C. / Yuan, L. C. / Frampton, M. / Begum, R. / Eltahir, Z. et al. | 2018
- 237
-
Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patientsLambertini, M. / Goldrat, O. / Ferreira, A. R. / Dechene, J. / Azim Jr, H. A. / Desir, J. / Delbaere, A. / de Roodenbeke, M.-D. K. / de Azambuja, E. / Ignatiadis, M. et al. | 2018
- 244
-
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapyBlackwell, K. / Gascon, P. / Krendyukov, A. / Gattu, S. / Li, Y. / Harbeck, N. et al. | 2018
- 250
-
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanomaPollack, M. H. / Betof, A. / Dearden, H. / Rapazzo, K. / Valentine, I. / Brohl, A. S. / Ancell, K. K. / Long, G. V. / Menzies, A. M. / Eroglu, Z. et al. | 2018
- 256
-
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphomaKwong, Y. L. / Kim, S. J. / Tse, E. / Oh, S. Y. / Kwak, J. Y. / Eom, H. S. / Do, Y. R. / Mun, Y. C. / Lee, S. R. / Shin, H. J. et al. | 2018
- 264
-
The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiationRiester, M. / Xu, Q. / Moreira, A. / Zheng, J. / Michor, F. / Downey, R. J. et al. | 2018
- 271
-
Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanomaGhorani, E. / Rosenthal, R. / McGranahan, N. / Reading, J. L. / Lynch, M. / Peggs, K. S. / Swanton, C. / Quezada, S. A. et al. | 2018
- 280
-
The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation OncologyKirova, Y. M. / Carroll, S. / Fourquet, A. / Offersen, B. / Aristei, C. / Chen, J.-Y. et al. | 2018
- 281
-
Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al.Dubsky, P. / Curigliano, G. / Burstein, H. J. / Winer, E. P. / Gnant, M. / Loibl, S. / Colleoni, M. / Regan, M. M. / Piccart-Gebhart, M. / Senn, H.-J. et al. | 2018
- 282
-
Analyzing the impact of depth of response on survival in patients with metastatic non-small-cell lung cancerWeber, S. / Wolkewitz, M. / Schumacher, M. et al. | 2018
- 283
-
Stevens–Johnson syndrome during nivolumab treatment of NSCLCSalati, M. / Pifferi, M. / Baldessari, C. / Bertolini, F. / Tomasello, C. / Cascinu, S. / Barbieri, F. et al. | 2018
- 284
-
Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?Gelsomino, F. / Fiorentino, M. / Zompatori, M. / Poerio, A. / Melotti, B. / Sperandi, F. / Gargiulo, M. / Borghi, C. / Ardizzoni, A. et al. | 2018
- 286
-
Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipientBiondani, P. / De Martin, E. / Samuel, D. et al. | 2018
- 287
-
Curcumin dietary supplements and everolimus-based cancer treatmentMir, O. / Ropert, S. / Chamseddine, A. N. / Paci, A. et al. | 2018
- 289
-
Ten thousand attentive hours, rapid learning, dissemination of knowledge and the future of experience-based care in germ-cell tumorsNichols, C. / Tandstad, T. / Lowrance, W. / Daneshmand, S. et al. | 2018
- 290
-
Prostate cancers that ‘Wnt’ respond to abirateroneLinch, M. / Attard, G. et al. | 2018
- 292
-
Male breast cancer: pink ribbon bluesFrancis, P. A. et al. | 2018
- 293
-
Pharmacogenomics: time to rethink its role in precision medicineWillis, J. A. / Vilar, E. et al. | 2018
- 295
-
New antiemetics: facing the current challengeScotté, F. et al. | 2018
- 297
-
Outcome prediction in patients with localized soft tissue sarcoma: which tool is the best?Kasper, B. / Wardelmann, E. et al. | 2018
- 298
-
Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for itPrasad, V. et al. | 2018
- 301
-
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platformsKordbacheh, T. / Honeychurch, J. / Blackhall, F. / Faivre-Finn, C. / Illidge, T. et al. | 2018
- 311
-
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?Yang, M. / Forbes, M. E. / Bitting, R. L. / O'Neill, S. S. / Chou, P. C. / Topaloglu, U. / Miller, L. D. / Hawkins, G. A. / Grant, S. C. / DeYoung, B. R. et al. | 2018
- 324
-
Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?Figlin, R. A. / Leibovich, B. C. / Stewart, G. D. / Negrier, S. et al. | 2018
- 332
-
Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomasKarmali, R. / Kimby, E. / Ghielmini, M. / Flinn, I. W. / Gordon, L. I. / Zucca, E. et al. | 2018
- 341
-
Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumorsAlbany, C. / Adra, N. / Snavely, A. C. / Cary, C. / Masterson, T. A. / Foster, R. S. / Kesler, K. / Ulbright, T. M. / Cheng, L. / Chovanec, M. et al. | 2018
- 347
-
Improved survival in metastatic germ-cell cancerFankhauser, C. D. / Sander, S. / Roth, L. / Beyer, J. / Hermanns, T. et al. | 2018
- 352
-
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisoneWang, L. / Dehm, S. M. / Hillman, D. W. / Sicotte, H. / Tan, W. / Gormley, M. / Bhargava, V. / Jimenez, R. / Xie, F. / Yin, P. et al. | 2018
- 361
-
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)Bamias, A. / Tzannis, K. / Harshman, L. C. / Crabb, S. J. / Wong, Y. N. / Kumar Pal, S. / De Giorgi, U. / Ladoire, S. / Agarwal, N. / Yu, E. Y. et al. | 2018
- 370
-
Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?Blinman, P. L. / Davis, I. D. / Martin, A. / Troon, S. / Sengupta, S. / Hovey, E. / Coskinas, X. / Kaplan, R. / Ritchie, A. / Meade, A. et al. | 2018
- 377
-
Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort studyPettersson, A. / Robinson, D. / Garmo, H. / Holmberg, L. / Stattin, P. et al. | 2018
- 386
-
Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancerYang, D. D. / Krasnova, A. / Nead, K. T. / Choueiri, T. K. / Hu, J. C. / Hoffman, K. E. / Yu, J. B. / Spratt, D. E. / Feng, F. Y. / Trinh, Q. D. et al. | 2018
- 392
-
Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302Cella, D. / Traina, S. / Li, T. / Johnson, K. / Ho, K. F. / Molina, A. / Shore, N. D. et al. | 2018
- 398
-
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trialEk, L. / Gezelius, E. / Bergman, B. / Bendahl, P. O. / Anderson, H. / Sundberg, J. / Wallberg, M. / Falkmer, U. / Verma, S. / Belting, M. et al. | 2018
- 405
-
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramCardoso, F. / Bartlett, J. M. / Slaets, L. / van Deurzen, C. H. / van Leeuwen-Stok, E. / Porter, P. / Linderholm, B. / Hedenfalk, I. / Schröder, C. / Martens, J. et al. | 2018
- 418
-
Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor boardSomashekhar, S. P. / Sepúlveda, M. J. / Puglielli, S. / Norden, A. D. / Shortliffe, E. H. / Rohit Kumar, C. / Rauthan, A. / Arun Kumar, N. / Patil, P. / Rhee, K. et al. | 2018
- 431
-
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancerProvencher, D. M. / Gallagher, C. J. / Parulekar, W. R. / Ledermann, J. A. / Armstrong, D. K. / Brundage, M. / Gourley, C. / Romero, I. / Gonzalez-Martin, A. / Feeney, M. et al. | 2018
- 439
-
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trialAbad, A. / Martínez-Balibrea, E. / Viéitez, J. M. / Alonso-Orduña, V. / García Alfonso, P. / Manzano, J. L. / Massutí, B. / Benavides, M. / Carrato, A. / Zanui, M. et al. | 2018
- 445
-
Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trialNoordman, B. J. / Verdam, M. G. / Lagarde, S. M. / Shapiro, J. / Hulshof, M. C. / van Berge Henegouwen, M. I. / Wijnhoven, B. P. / Nieuwenhuijzen, G. A. / Bonenkamp, J. J. / Cuesta, M. A. et al. | 2018
- 452
-
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)Zhang, L. / Lu, S. / Feng, J. / Dechaphunkul, A. / Chang, J. / Wang, D. / Chessari, S. / Lanzarotti, C. / Jordan, K. / Aapro, M. et al. | 2018
- 459
-
The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcomaBertucci, F. / De Nonneville, A. / Finetti, P. / Perrot, D. / Nilbert, M. / Italiano, A. / Le Cesne, A. / Skubitz, K. M. / Blay, J. Y. / Birnbaum, D. et al. | 2018
- 466
-
Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomasUdager, A. M. / McHugh, J. B. / Goudsmit, C. M. / Weigelin, H. C. / Lim, M. S. / Elenitoba-Johnson, K. S. / Betz, B. L. / Carey, T. E. / Brown, N. A. et al. | 2018
- 472
-
Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortiumOrdóñez-Mena, J. M. / Walter, V. / Schöttker, B. / Jenab, M. / O’Doherty, M. G. / Kee, F. / Bueno-de-Mesquita, B. / Peeters, P. H. / Stricker, B. H. / Ruiter, R. et al. | 2018
- 484
-
Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern ItalyBoffetta, P. / Righi, L. / Ciocan, C. / Pelucchi, C. / La Vecchia, C. / Romano, C. / Papotti, M. / Pira, E. et al. | 2018
- 490
-
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanomaLee, R. J. / Gremel, G. / Marshall, A. / Myers, K. A. / Fisher, N. / Dunn, J. A. / Dhomen, N. / Corrie, P. G. / Middleton, M. R. / Lorigan, P. et al. | 2018
- 497
-
Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasisMcTyre, E. / Ayala-Peacock, D. / Contessa, J. / Corso, C. / Chiang, V. / Chung, C. / Fiveash, J. / Ahluwalia, M. / Kotecha, R. / Chao, S. et al. | 2018
- 504
-
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies IISestak, I. / Smith, S. G. / Howell, A. / Forbes, J. F. / Cuzick, J. et al. | 2018
- 510
-
The predictive value of interim FDG-PET in early-stage Hodgkin lymphoma is not well establishedAdams, H. J. / Kwee, T. C. et al. | 2018
- 512
-
Goserelin does not preserve ovarian function against chemotherapy-induced damageOktay, K. / Taylan, E. / Rodriguez-Wallberg, K. A. / Bedoschi, G. / Turan, V. / Pacheco, F. et al. | 2018
- 513
-
Nivolumab-associated bone marrow necrosisHilal, T. / Bansal, P. / Kelemen, K. / Slack, J. et al. | 2018
- 514
-
A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitorLeroy, L. / Lafarge, X. / Blouin, L. / Bijou, F. / Durrieu, F. / Olivier, E. / Le Moulec, S. et al. | 2018
- 516
-
Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis BLin, G. / Zhuang, W. / Chen, X. H. / Huang, C. / Lin, X. D. / Huang, Y. J. / Li, C. et al. | 2018
- 517
-
Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancerGuihot, A. / Marcelin, A. G. / Massiani, M. A. / Samri, A. / Soulié, C. / Autran, B. / Spano, J. P. et al. | 2018
- 518
-
Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitorsMichot, J. M. / Pruvost, R. / Mateus, C. / Champiat, S. / Voisin, A. L. / Marabelle, A. / Lambotte, O. et al. | 2018
- 520
-
Toxicity adjustment in the ESMO-MCBS: a gestalt approach?Del Paggio, J. C. et al. | 2018
- 521
-
Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del PaggioCherny, N. I. / Dafni, U. / Bogaerts, J. / Latino, N. J. / Pentheroudakis, G. / Douillard, J. Y. / Tabernero, J. / Zielinski, C. / Piccart, M. J. / de Vries, E. G. et al. | 2018
- 523
-
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patientsTrédan, O. / Ménétrier-Caux, C. / Ray-Coquard, I. / Garin, G. / Cropet, C. / Verronèse, E. / Bachelot, T. / Rebattu, P. / E Heudel, P. / Cassier, P. et al. | 2018
- 524
-
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabFerrucci, P. F. / Ascierto, P. A. / Pigozzo, J. / Del Vecchio, M. / Maio, M. / Antonini Cappellini, G. C. / Guidoboni, M. / Queirolo, P. / Savoia, P. / Mandalà, M. et al. | 2018
- 525
-
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemiaLadetto, M. / Buske, C. / Hutchings, M. / Dreyling, M. / Gaidano, G. / Le Gouill, S. / Luminari, S. / Pott, C. / Zamò, A. / Zucca, E. et al. | 2018
- 526
-
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)Tai, W. M. / Yong, W. P. / Lim, C. / Low, L. S. / Tham, C. K. / Koh, T. S. / Ng, Q. S. / Wang, W. W. / Wang, L. Z. / Hartono, S. et al. | 2018
- 527
-
The US Food and Drug Administration’s use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generationDeLoughery, E. P. / Prasad, V. et al. | 2018
- 527
-
RAISEing VEGF-D’s importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patientsCarmeliet, P. / Li, X. / Treps, L. / Conradi, L.-C. / Loges, S. et al. | 2018
- 532
-
Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?Vivancos, A. / Élez, E. / Salazar, R. et al. | 2018
- 534
-
Outcome in colorectal cancer—tumour, stroma and so much morePark J. H. / McMillan, D. C. et al. | 2018
- 535
-
Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancerAbbosh, C. / Swanton, C. / Birkbak, N. J. et al. | 2018
- 537
-
Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningiomaDu, S. / Santagata, S. et al. | 2018
- 540
-
Phase I–II trial designs: how early should efficacy guide the dose recommendation process?Paoletti, X. / Postel-Vinay, S. et al. | 2018
- 542
-
First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanomaTurajlic, S. / Gore, M. / Larkin, J. et al. | 2018
- 544
-
ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphomaBuske, C. / Hutchings, M. / Ladetto, M. / Goede, V. / Mey, U. / Soubeyran, P. / Spina, M. / Stauder, R. / Trněný, M. / Wedding, U. et al. | 2018
- 563
-
Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolutionVenkatesan, S. / Rosenthal, R. / Kanu, N. / McGranahan, N. / Bartek, J. / Quezada, S. A. / Hare, J. / Harris, R. S. / Swanton, C. et al. | 2018
- 573
-
Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapiesKorn, E. L. / Freidlin, B. et al. | 2018
- 578
-
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemiaKhoury, H. J. / Gambacorti-Passerini, C. / Brümmendorf, T. H. et al. | 2018
- 588
-
Next-generation immunotherapies for lymphoma: one foot in the futureManson, G. / Houot, R. et al. | 2018
- 602
-
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III studyTabernero, J. / Hozak, R. R. / Yoshino, T. / Cohn, A. L. / Obermannova, R. / Bodoky, G. / Garcia-Carbonero, R. / Ciuleanu, T.-E. / Portnoy, D. C. / Prausová, J. et al. | 2018
- 610
-
Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancerSchou, J. V. / Larsen, F. O. / Sørensen, B. S. / Abrantes, R. / Boysen, A. K. / Johansen, J. S. / Jensen, B. V. / Nielsen, D L. / Spindler, K. L. et al. | 2018
- 616
-
Prognostic markers for colorectal cancer: estimating ploidy and stromaDanielsen, H. E. / Hveem T. S. / Domingo, E. / Pradhan, M. / Kleppe, A. / Syvertsen, R. A. / Kostolomov, I. / Nesheim, J. A. / Askautrud, H. A. / Nesbakken, A. et al. | 2018
- 624
-
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trialYamada, Y. / Denda, T. / Gamoh, M. / Iwanaga, I. / Yuki, S. / Shimodaira, H. / Nakamura, M. / Yamaguchi, T. / Ohori, H. / Kobayashi, K. et al. | 2018
- 632
-
A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267Gong, J. / Tian, J. / Lou, J. / Wang, X. / Ke, J. / Li, J. / Yang, Y. / Gong, Y. / Zhu, Y / Zou, D. et al. | 2018
- 640
-
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancerCondorelli, R. / Spring, L. / O’Shaughnessy, J. / Lacroix, L. / Bailleux, C. / Scott, V. / Dubois, J. / Nagy, R. J. / Lanman, R. B. / Iafrate, A. J. et al. | 2018
- 646
-
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studySwain, S. M. / Ewer, M. S. / Viale, G. / Delaloge, S. / Ferrero, J.-M. / Verrill, M. / Colomer, R. / Vieira, C. / Werner, T. L. / Douthwaite, H. et al. | 2018
- 654
-
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)Sharma, P. / Barlow, W. E. / Godwin, A. K. / Pathak, H. / Isakova, K. / Williams, D. / Timms, K. M. / Hartman, A. R. / Wenstrup, R. J. / Linden, H. M. et al. | 2018
- 661
-
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trialGennari, A. / Sun, Z. / Hasler-Strub, U. / Colleoni, M. / Kennedy, M. J. / Von Moos, R. / Cortés, J. / Vidal, M. J. / Hennessy, B. / Walshe, J. et al. | 2018
- 669
-
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastasesTurner, N. C. / Finn, R. S. / Martin, M. / Im, S.-A. / DeMichele, A. / Ettl, J. / Diéras, V. / Moulder, S. / Lipatov, O. / Colleoni, M. et al. | 2018
- 681
-
Progestin-associated shift of meningioma mutational landscapePeyre, M. / Gaillard, S. / de Marcellus, C. / Giry, M. / Bielle, F. / Villa, C. / Boch, A. L. / Loiseau, H. / Baussart, B. / Cazabat, L. et al. | 2018
- 687
-
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trialsGoss, G. / Tsai, C.-M. / Shepherd, F. A. / Ahn, M.-J. / Bazhenova, L. / Crinò, L. / de Marinis, F. / Felip, E. / Morabito, A. / Hodge, R. et al. | 2018
- 694
-
Phase I–II clinical trial design: a state-of-the-art paradigm for dose findingYan, F. / Thall, P. F. / Lu, K. H. / Gilbert, M. R. / Yuan, Y. et al. | 2018
- 700
-
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasmaKrug, A. K. / Enderle, D. / Karlovich, C. / Priewasser, T. / Bentink, S. / Spiel, S. / Brinkmann, K. / Emenegger, J. / Grimm, D. G. / Castellanos-Rizaldos, E. et al. | 2018
- 707
-
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trialWitzig, T. E. / Tobinai, K. / Rigacci, L. / Ikeda, T. / Vanazzi, A. / Hino, M. / Shi, Y. / Mayer, J. / Costa, L. J. / Bermudez Silva, C. D. et al. | 2018
- 715
-
Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centersFossard, G. / Broussais, F. / Coelho, I. / Bailly, S. / Nicolas-Virelizier, E. / Toussaint,E. / Lancesseur, C. / Le Bras, F. / Willems, E. / Tchernonog, E. et al. | 2018
- 724
-
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphomaHerrera, A. F. / Palmer, J. / Martin, P. / Armenian, S. / Tsai, N.-C. / Kennedy, N. / Sahebi, F. / Cao, T. / Budde, L. E. / Mei, M. et al. | 2018
- 731
-
A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)Frikha, M. / Auperin, A. / Tao, Y. / Elloumi, F. / Toumi, N. / Blanchard, P. / Lang, P. / Sun, S. / Racadot, S. / Thariat, J. et al. | 2018
- 737
-
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapyFriedlander, M. / Rau, J. / Lee, C.K. / Meier, W. / Lesoin, A. / Kim, J.-W. / Poveda, A. / Buck, M. / Scambia, G. / Shimada, M. et al. | 2018
- 744
-
Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancerKhosrow-Khavar, F. / Yin, H. / Barkun, A. / Bouganim, N. / Azoulay, L. et al. | 2018
- 749
-
Body mass index and 20 specific cancers: re-analyses of dose–response meta-analyses of observational studiesChoi, E. K. / Park, H. B. / Lee, K. H. / Park, J. H. / Eisenhut, M. / van der Vliet, H. J. / Kim, G. / Shin, J. I. et al. | 2018
- 758
-
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’Schöffski, P. / Wozniak, A. / Kasper, B. / Aamdal, A. / Leahy, M. G. / Rutkowski, P. / Bauer, S. / Gelderblom, H. / Italiano, A. / Lindner, L. H. et al. | 2018
- 766
-
Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATEGaspar, N. / Marshall, L. V. / Binner , D. / Herold, R. / Rousseau, R. / Blanc, P. / Capdeville, R. / Carleer, J. / Copland, C. / Kerloeguen, Y. et al. | 2018
- 772
-
Medical oncologists’ perception of antiestrogen therapy benefit in premenopausal women with hormone receptor-positive early-stage breast cancerPatel, R. / Maxwell, S. / Yan, D. / Dressler, E. V. / Romond, E. H. / Mathew, A. et al. | 2018
- 773
-
Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapiesDel Paggio, J. C. / Sullivan, R. / Hopman, W. M. / Booth, C. M. et al. | 2018
- 774
-
Reply to the letter to the editor ‘Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies’Cherny, N. I. / Dafni, U. / Bogaerts, J. / Latino, N. J. / Pentheroudakis, G. / Douillard, J.-Y. / Tabernero, J. / Zielinski, C. / Piccart, M. J. / de Vries, E. G. E. et al. | 2018
- 776
-
Crossover is not associated with faster trial accrualChen, E. Y. / Prasad, V. et al. | 2018
- 777
-
Nivolumab in non-small-cell lung cancer with EGFR mutationYoshida, H. / Kim, Y. H. / Ozasa, H. / Nagai, H. / Sakamori, Y. / Tsuji, T. / Nomizo, T. / Yasuda, Y. / Funazo, T. / Hirai, T. et al. | 2018
- 779
-
Concurrent cisplatin and radiotherapy versus cetuximab and radiotherapy, an unsolved problemGuler, O. C. / Onal, C. / Ozyar, E. et al. | 2018
- 779
-
Reply to the letter to the editor ‘Concurrent cisplatin and radiotherapy versus cetuximab and radiotherapy, an unsolved problem’ by Guler et al.Ghi, M. G. / Ferrari, D. et al. | 2018
- 780
-
Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancerOtsubo, K. / Seki, N. / Nakanishi, Y. / Okamoto, I. et al. | 2018
- 781
-
The ESMO Precision Medicine GlossaryJørgensen, J. T. et al. | 2018
- 783
-
Genomic medicine France 2025Lethimonnier, F. / Levy, Y. et al. | 2018
- 784
-
Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes ProjectTurnbull, C. et al. | 2018
- 787
-
ESR1 and endocrine therapy resistance: more than just mutationsPiscuoglio, S. / Ng, C. K. / Weigelt, B. / Chandarlapaty, S. / Reis-Filho, J. S. et al. | 2018
- 789
-
Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLCVanden Bempt, I. / Wauters, E. / Vansteenkiste, J. et al. | 2018
- 791
-
Time is up for PD-L1 testing standardization in lung cancerDacic, S. et al. | 2018
- 792
-
Developing androgen receptor targeting for salivary gland cancersHo, A. L. et al. | 2018
- 794
-
Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN)Vigneswara, V. / Kong, A. et al. | 2018
- 796
-
Taking it in the chin: vitamin K1 for the prevention of acneiform rashLacouture, M. E. et al. | 2018
- 798
-
Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroupsAdam, J. / Postel-Vinay, S. et al. | 2018
- 799
-
Computational prediction of neoantigens: do we need more data or new approaches?Eklund, A. C. / Szallasi, Z. et al. | 2018
- 801
-
Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matterKlempner, S. J. / Chao, J. et al. | 2018
- 803
-
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysisTrone, J. C. / Ollier, E. / Chapelle, C. / Bertoletti, L. / Cucherat, M. / Mismetti, P. / Magné, N. / Laporte, S. et al. | 2018
- 812
-
Epigenetic modifiers as new immunomodulatory therapies in solid tumoursAspeslagh, S. / Morel, D. / Soria, J. C. / Postel-Vinay, S. et al. | 2018
- 825
-
Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: a systematic review and meta-analysesCarr, P. R. / Alwers, E. / Bienert, S. / Weberpals, J. / Kloor, M. / Brenner, H. / Hoffmeister, M. et al. | 2018
- 835
-
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic reviewArnold, D. / Prager, G. W. / Quintela, A. / Stein, A. / Moreno Vera, S. / Mounedji, N. / Taieb, J. et al. | 2018
- 857
-
Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)†Ahlen, J. / Ahuja, N. / Albertsmeier, M. / Al-Refaie, W. B. / Andtbacka, R. / Angele, M. / Bagaria, S. P. / Baldini, E. / Barretta, F. / Beasley, G. et al. | 2018
- 872
-
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancerHartmaier, R. J. / Trabucco, S. E. / Priedigkeit, N. / Chung, J. H. / Parachoniak, C. A. / Vanden Borre, P. / Morley, S. / Rosenzweig, M. / Gay, L. M. / Goldberg, M. E. et al. | 2018
- 881
-
Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancerCortes, J. / Perez-Garcia, J. / Levy, C. / Gómez Pardo, P. / Bourgeois, H. / Spazzapan, S. / Martínez-Jañez, N. / Chao, T. C. / Espié, M. / Nabholtz, J. M. et al. | 2018
- 888
-
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trialRugo, H. S. / Diéras, V. / Gelmon, K. A. / Finn, R. S. / Slamon, D. J. / Martin, M. / Neven, P. / Shparyk, Y. / Mori, A. / Lu, D. R. et al. | 2018
- 895
-
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysisBareche, Y. / Venet, D. / Ignatiadis, M. / Aftimos, P. / Piccart, M. / Rothe, F. / Sotiriou, C. et al. | 2018
- 903
-
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancersBirkbak, N. J. / Li, Y. / Pathania, S. / Greene-Colozzi, A. / Dreze, M. / Bowman-Colin, C. / Sztupinszki, Z. / Krzystanek, M. / Diossy, M. / Tung, N. et al. | 2018
- 910
-
Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countriesOskay-Özcelik, G. / Alavi, S. / Richter, R. / Keller, M. / Chekerov, R. / Cecere, S. C. / Cormio, G. / Joly, F. / Kurtz, J. E. / du Bois, A. et al. | 2018
- 917
-
Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II studyBanerjee, S. / Oza, A. M. / Birrer, M. J. / Hamilton, E. P. / Hasan, J. / Leary, A. / Moore, K. N. / Mackowiak-Matejczyk, B. / Pikiel, J. / Ray-Coquard, I. et al. | 2018
- 924
-
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONODell’Aquila, E. / Cremolini, C. / Zeppola, T. / Lonardi, S. / Bergamo, F. / Masi, G. / Stellato, M. / Marmorino, F. / Schirripa, M. / Urbano, F. et al. | 2018
- 931
-
Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trialSobhani, I. / Itti, E. / Luciani, A. / Baumgaertner, I. / Layese, R. / André, T. / Ducreux, M. / Gornet, J. M. / Goujon, G. / Aparicio, T. et al. | 2018
- 938
-
A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinomaLi, X. C. / Wang, M. Y. / Yang, M. / Dai, H. J. / Zhang, B. F. / Wang, W. / Chu, X. L. / Wang, X. / Zheng, H. / Niu, R. F. et al. | 2018
- 945
-
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsyLi, Y. S. / Jiang, B. Y. / Yang, J. J. / Zhang, X. C. / Zhang, Z. / Ye, J. Y. / Zhong, W. Z. / Tu, H. Y. / Chen, H. J. / Wang, Z. et al. | 2018
- 953
-
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancerAdam, J. / Le Stang, N. / Rouquette, I. / Cazes, A. / Badoual, C. / Pinot-Roussel, H. / Tixier, L. / Danel, C. / Damiola, F. / Damotte, D. et al. | 2018
- 959
-
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastasesVokes, E. E. / Ready, N. / Felip, E. / Horn, L. / Burgio, M. A. / Antonia, S. J. / Arén Frontera, O. / Gettinger, S. / Holgado, E. / Spigel, D. et al. | 2018
- 966
-
Genetic landscape of ultra-stable chronic lymphocytic leukemia patientsRaponi, S. / Del Giudice, I. / Marinelli, M. / Wang, J. / Cafforio, L. / Ilari, C. / Piciocchi, A. / Messina, M. / Bonina, S. / Tavolaro, S. et al. | 2018
- 973
-
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patientsRöllig, C. / Kramer, M. / Gabrecht, M. / Hänel, M. / Herbst, R. / Kaiser, U. / Schmitz, N. / Kullmer, J. / Fetscher, S. / Link, H. et al. | 2018
- 979
-
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinomaFushimi, C. / Tada, Y. / Takahashi, H. / Nagao, T. / Ojiri, H. / Masubuchi, T. / Matsuki, T. / Miura, K. / Kawakita, D. / Hirai, H. et al. | 2018
- 985
-
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)Machiels, J. P. / Bossi, P. / Menis, J. / Lia, M. / Fortpied, C. / Liu, Y. / Lhommel, R. / Lemort, M. / Schmitz, S. / Canevari, S. et al. | 2018
- 992
-
Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study (JCOG0701)Kodaira, T. / Kagami, Y. / Shibata, T. / Shikama, N. / Nishimura, Y. / Ishikura, S. / Nakamura, K. / Saito, Y. / Matsumoto, Y. / Teshima, T. et al. | 2018
- 998
-
Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neckAwan, M. J. / Nedzi, L. / Wang, D. / Tumati, V. / Sumer, B. / Xie, X. J. / Smith, I. / Truelson, J. / Hughes, R. / Myers, L. L. et al. | 2018
- 1004
-
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)Tahara, M. / Kiyota, N. / Yokota, T. / Hasegawa, Y. / Muro, K. / Takahashi, S. / Onoe, T. / Homma, A. / Taguchi, J. / Suzuki, M. et al. | 2018
- 1010
-
EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicityHofheinz, R. D. / Lorenzen, S. / Trojan, J. / Ocvirk, J. / Ettrich, T. J. / Al-Batran, S. E. / Schulz, H. / Homann, N. / Feustel, H. P. / Schatz, M. et al. | 2018
- 1016
-
European cancer mortality predictions for the year 2018 with focus on colorectal cancerMalvezzi, M. / Carioli, G. / Bertuccio, P. / Boffetta, P. / Levi, F. / La Vecchia, C. / Negri, E. et al. | 2018
- 1023
-
CHK1 inhibition in soft-tissue sarcomas: biological and clinical implicationsLaroche-Clary, A. / Lucchesi, C. / Rey, C. / Verbeke, S. / Bourdon, A. / Chaire, V. / Algéo, M. P. / Cousin, S. / Toulmonde, M. / Vélasco, V. et al. | 2018
- 1030
-
Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity informationKim, S. / Kim, H. S. / Kim, E. / Lee, M. G. / Shin, E. C. / Paik, S. et al. | 2018
- 1037
-
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patientsKim, S. T. / Banks, K. C. / Pectasides, E. / Kim, S. Y. / Kim, K. / Lanman, R. B. / Talasaz, A. / An, J. / Choi, M. G. / Lee, J. H. et al. | 2018
- 1049
-
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancerGuibert, N. / Hu, Y. / Feeney, N. / Kuang, Y. / Plagnol, V. / Jones, G. / Howarth, K. / Beeler, J. F. / Paweletz, C. P. / Oxnard, G. R. et al. | 2018
- 1056
-
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trialBuisseret, L. / Pommey, S. / Allard, B. / Garaud, S. / Bergeron, M. / Cousineau, I. / Ameye, L. / Bareche, Y. / Paesmans, M. / Crown, J. P. et al. | 2018
- 1063
-
Funding sources of practice-changing trialsDogan, S. / Yamamoto-Ibusuki, M. / Andre, F. et al. | 2018
- 1065
-
PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?Lavolé, A. / Guihot, A. / Veyri, M. / Lambotte, O. / Autran, B. / Cloarec, N. / Le Garff, G. / Flament, T. / Cadranel, J. / Spano, J. P. et al. | 2018
- 1067
-
PD-1 blockade with nivolumab in endemic Kaposi sarcomaDelyon, J. / Bizot, A. / Battistella, M. / Madelaine, I. / Vercellino, L. / Lebbé, C. et al. | 2018
- 1067
-
Immune-related adverse events of immune checkpoint inhibitors and the impact of sex—what we know and what we need to learnÖzdemir, B. C. / Coukos, G. / Wagner, A. D. et al. | 2018
- 1069
-
Recommendations for the clinical management of the elderly patient with malignant lymphomaSpecht, L. / Aleman, B. / Eich, H. / Illidge, T. M. / Kirova, Y. / Mikhaeel, N. G. / Ricardi, U. / Yahalom, J. et al. | 2018
- 1070
-
ESMO-MCBS v1.1: statistical and patient-relevant shortcomingsEmprechtinger, R. / Grössmann, N. / Wild, C. et al. | 2018
- 1072
-
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-upKadara, H. / Choi, M. / Zhang, J. / Parra, E. R. / Rodriguez-Canales, J. / Gaffney, S. G. / Zhao, Z. / Behrens, C. / Fujimoto, J. / Chow, C. et al. | 2018
- 1073
-
Crizotinib: from discovery to accelerated development to front-line treatmentBlackhall, F. / Cappuzzo, F. et al. | 2018
- 1074
-
Second primary malignancies in multiple myeloma: an overview and IMWG consensusMusto, P. / Anderson, K. C. / Attal, M. / Richardson, P. G. / Badros, A. / Hou, J. / Comenzo, R. / Du, J. / Durie, B. G. / San Miguel, J. et al. | 2018
- 1075
-
Corrigendum: mdw197, mdw434 and mdw695| 2018
- 1076
-
Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancerJanku, F. / Johnson, L. K. / Karp, D. D. / Atkins, J. T. / Singleton, P. A. / Moss, J. et al. | 2018
- 1077
-
Surgery for patients with ‘lower grade’ glioma: putting assumptions, beliefs and convictions into perspectiveWeller, M. et al. | 2018
- 1078
-
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLCAguiar, P. N. / Perry, L. A. / Penny-Dimri, J. / Babiker, H. / Tadokoro, H. / de Mello, R. A. / Lopes, G. L. et al. | 2018
- 1079
-
When is crossover desirable in cancer drug trials and when is it problematic?Haslam, A. / Prasad, V. et al. | 2018
- 1081
-
Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?Creutzberg, C. L. / Bosse, T. et al. | 2018
- 1083
-
Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?Montagut, C. / Tsui, D. W. / Diaz, L. A. et al. | 2018
- 1084
-
The case for ‘successfully’ treating hormone naïve metastatic prostate cancerEfstathiou, E. et al. | 2018
- 1086
-
Antibody therapy targeting CD19 for B-cell non-Hodgkin’s lymphomaMakita, S. / Tobinai, K. et al. | 2018
- 1089
-
HPV status, like politics, is local—evaluating p16 staining and a new staging system in a Dutch cohort of oropharynx cancerOrosco, R. K. / Califano, J. A. et al. | 2018
- 1090
-
It is time to rethink weight loss in cancerCurrow, D. C. / LeBlanc, T. W. et al. | 2018
- 1092
-
Adding a new analytical procedure with clinical interpretation in the tool box of survival analysisUno, H. / Claggett, B. / Tian, L. / Fu, H. / Huang, B. / Kim, D. H. / Wei, L. J. et al. | 2018
- 1094
-
Circulating tumor DNA detection in hepatocellular carcinomaCabel, L. / Proudhon, C. / Buecher, B. / Pierga, J. Y. / Bidard, F. C. et al. | 2018
- 1096
-
Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?Geffen, D. B. et al. | 2018
- 1099
-
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?Sobrero, A. / Grothey, A. / Iveson, T. / Labianca, R. / Yoshino, T. / Taieb, J. / Maughan, T. / Buyse, M. / André, T. / Meyerhardt, J. et al. | 2018
- 1108
-
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancerSiena, S. / Sartore-Bianchi, A. / Marsoni, S. / Hurwitz, H. I. / McCall, S. J. / Penault-Llorca, F. / Srock, S. / Bardelli, A. / Trusolino, L. et al. | 2018
- 1120
-
Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical reviewIacoboni, G. / Zucca, E. / Ghielmini, M. / Stathis, A. et al. | 2018
- 1130
-
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directionsHaddad, R. I. / Posner, M. / Hitt, R. / Cohen, E. E. / Schulten, J. / Lefebvre, J. L. / Vermorken, J. B. et al. | 2018
- 1141
-
Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trialsde van der Schueren, M. A. / Laviano, A. / Blanchard, H. / Jourdan, M. / Arends, J. / Baracos, V. E. et al. | 2018
- 1154
-
Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysisBenke, I. N. / Leitzmann, M. F. / Behrens, G. / Schmid, D. et al. | 2018
- 1180
-
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case seriesKommoss, S. / McConechy, M. K. / Kommoss, F. / Leung, S. / Bunz, A. / Magrill, J. / Britton, H. / Grevenkamp, F. / Karnezis, A. et al. | 2018
- 1189
-
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerPiccirillo, M. C. / Scambia, G. / Bologna, A. / Signoriello, S. / Vergote, I. / Baumann, K. / Lorusso, D. / Murgia, V. / Sorio, R. / Ferrandina, G. et al. | 2018
- 1195
-
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxaneMartin, M. / Campone, M. / Bondarenko, I. / Sakaeva, D. / Krishnamurthy, S. / Roman, L. / Lebedeva, L. / Vedovato, J. C. / Aapro, M. et al. | 2018
- 1203
-
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCruz, C. / Castroviejo-Bermejo, M. / Gutiérrez-Enríquez, S. / Llop-Guevara, A. / Ibrahim, Y. H. / Gris-Oliver, A. / Bonache, S. / Morancho, B. / Bruna, A. / Rueda, O. M. et al. | 2018
- 1211
-
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter studyBachet, J. B. / Bouché, O. / Taieb, J. / Dubreuil, O. / Garcia, M. L. / Meurisse, A. / Normand, C. / Gornet, J. M. / Artru, P. / Louafi, S. et al. | 2018
- 1220
-
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapyKang, Y. K. / Ryu, M. H. / Park, S. H. / Kim, J. G. / Kim, J. W. / Cho, S. H. / Park, Y. I. / Park, S. R. / Rha, S. Y. / Kang, M. J. et al. | 2018
- 1227
-
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancerSmeby, J. / Sveen, A. / Merok, M. A. / Danielsen, S. A. / Eilertsen, I. A. / Guren, M. G. / Dienstmann, R. / Nesbakken, A. / Lothe, R. A. et al. | 2018
- 1235
-
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolSydes, M. R. / Spears, M. R. / Mason, M. D. / Clarke, N. W. / Dearnaley, D. P. / de Bono, J. S. / Attard, G. / Chowdhury, S. / Cross, W. / Gillessen, S. et al. | 2018
- 1249
-
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysisVale, C. L. / Fisher, D. J. / White, I. R. / Carpenter, J. R. / Burdett, S. / Clarke, N. W. / Fizazi, K. / Gravis, G. / James, N. D. / Mason, M. D. et al. | 2018
- 1258
-
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor heterogeneity over timePasello, G. / Zago, G. / Lunardi, F. / Urso, L. / Kern, I. / Vlacic, G. / Grosso, F. / Mencoboni, M. / Ceresoli, G. L. / Schiavon, M. et al. | 2018
- 1266
-
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphomaJurczak, W. / Zinzani, P. L. / Gaidano, G. / Goy, A. / Provencio, M. / Nagy, Z. / Robak, T. / Maddocks, K. / Buske, C. / Ambarkhane, S. et al. | 2018
- 1273
-
Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testingNauta, I. H. / Rietbergen, M. M. / van Bokhoven, A. A. / Bloemena, E. / Lissenberg-Witte, B. I. / Heideman, D. A. / Baatenburg de Jong, R. J. / Brakenhoff, R. H. / Leemans, C. R. et al. | 2018
- 1280
-
Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assayGage, M. M. / Mylander, W. C. / Rosman, M. / Fujii, T. / Le Du, F. / Raghavendra, A. / Sinha, A. K. / Espinosa Fernandez, J. R. / James, A. / Ueno, N. T. et al. | 2018
- 1286
-
Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot studyNg, C. K. / Di Costanzo, G. G. / Tosti, N. / Paradiso, V. / Coto-Llerena, M. / Roscigno, G. / Perrina, V. / Quintavalle, C. / Boldanova, T. / Wieland, S. et al. | 2018
- 1292
-
MSR1 repeats modulate gene expression and affect risk of breast and prostate cancerRose, A. M. / Krishan, A. / Chakarova, C. F. / Moya, L. / Chambers, S. K. / Hollands, M. / Illingworth, J. C. / Williams, S. M. / McCabe, H. E. / Shah, A. Z. et al. | 2018
- 1304
-
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsItaliano, A. / Infante, J. R. / Shapiro, G. I. / Moore, K. N. / LoRusso, P. M. / Hamilton, E. / Cousin, S. / Toulmonde, M. / Postel-Vinay, S. / Tolaney, S. et al. | 2018
- 1312
-
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patientsRodríguez-Ruiz, M. E. / Perez-Gracia, J. L. / Rodríguez, I. / Alfaro, C. / Oñate, C. / Pérez, G. / Gil-Bazo, I. / Benito, A. / Inogés, S. / López-Diaz de Cerio, A. et al. | 2018
- 1320
-
Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancerLiang, F. / Zhang, S. / Wang, Q. / Li, W. et al. | 2018
- 1325
-
Restoration of conformation of mutant p53Green, J. A. / Von Euler, M. / Abrahmsen, L. B. et al. | 2018
- 1329
-
Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysisLiu, C. / Wang, L. / Zhuang, J. / Liu, L. / Zhou, C. / Feng, F. / Sun, C. et al. | 2018
- 1330
-
Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationaleMasuishi, T. / Taniguchi, H. / Sugiyama, K. / Kato, K. / Mitani, S. / Honda, K. / Narita, Y. / Kadowaki, S. / Ura, T. / Ando, M. et al. | 2018
- 1331
-
Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutationsTaniguchi, Y. / Tamiya, A. / Ishii, S. / Atagi, S. et al. | 2018
- 1333
-
Should de-escalation of bone-targeting agents be standard of care?Awan, A. / Hutton, B. / Clemons, M. et al. | 2018
- 1334
-
Nivolumab combined with ruxolitinib: antagonism or synergy?Debureaux, P. E. / Arrondeau, J. / Bouscary, D. / Goldwasser, F. et al. | 2018
- 1335
-
Reply to the letter to the editor ‘ESMO-MCBS v1.1: statistical and patient relevant shortcomings’ by Emprechtinger et al.Cherny, N. I. / Dafni, U. / Piccart, M. / Latino, N. J. / Douillard, J. Y. / Bogaerts, J. / Karlis, D. / Zygoura, P. / Pentheroudakis, G. / Tabernero, J. et al. | 2018
- 1339
-
Purchasing silenceTannock, I. F. / Joshua, A. M. et al. | 2018
- 1340
-
RET-fusions: a novel paradigm in colorectal cancerSantos, C. / Sanz-Pamplona, R. / Salazar, R. et al. | 2018
- 1343
-
Is there a future for EGFR targeted agents in esophageal cancer?Ilson, D. H. et al. | 2018
- 1344
-
The allure of ‘ALUR’Nagasaka, M. / Zhu, V. W. / Ou, S. H. et al. | 2018
- 1346
-
ARTE and craft of bevacizumab in elderly patients with glioblastomaSchiff, D. et al. | 2018
- 1348
-
Stringent vaccination of cancer patients: is it that important?Weber, T. / Ljungman, P. et al. | 2018
- 1349
-
Further evidence to support judicious use of antibiotics in patients with cancerLuke, J. J. / Pal, S. K. et al. | 2018
- 1351
-
Methylation in cell-free DNA for early cancer detectionFece de la Cruz, F. / Corcoran, R. B. et al. | 2018
- 1353
-
Divergent adaptation in thyroid cancersSottoriva, A. et al. | 2018
- 1354
-
Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Rieger, C. T. / Liss, B. / Mellinghoff, S. / Buchheidt, D. / Cornely, O. A. / Egerer, G. / Heinz, W. J. / Hentrich, M. / Maschmeyer, G. / Mayer, K. et al. | 2018
- 1366
-
Latest clinical evidence and further development of PARP inhibitors in ovarian cancerMirza, M. R. / Pignata, S. / Ledermann, J. A. et al. | 2018
- 1377
-
Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and futureAggelis, V. / Cunningham, D. / Lordick, F. / Smyth, E. C. et al. | 2018
- 1386
-
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)Ruhstaller, T. / Thuss-Patience, P. / Hayoz, S. / Schacher, S. / Knorrenschild, J. R. / Schnider, A. / Plasswilm, L. / Budach, W. / Eisterer, W. / Hawle, H. et al. | 2018
- 1394
-
RET fusions in a small subset of advanced colorectal cancers at risk of being neglectedPietrantonio, F. / Di Nicolantonio, F. / Schrock, A. B. / Lee, J. / Morano, F. / Fucà, G. / Nikolinakos, P. / Drilon, A. / Hechtman, J. F. / Christiansen, J. et al. | 2018
- 1402
-
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinomaAbou-Alfa, G. K. / Qin, S. / Ryoo, B. Y. / Lu, S. N. / Yen, C. J. / Feng, Y. H. / Lim, H. Y. / Izzo, F. / Colombo, M. / Sarker, D. et al. | 2018
- 1409
-
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR studyNovello, S. / Mazières, J. / Oh, I. J. / de Castro, J. / Migliorino, M. R. / Helland, . / Dziadziuszko, R. / Griesinger, F. / Kotb, A. / Zeaiter, A. et al. | 2018
- 1417
-
Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancerWang, H. / Agulnik, J. / Kasymjanova, G. / Wang, A. / Jiménez, P. / Cohen, V. / Small, D. / Pepe, C. / Sakr, L. / Fiset, P. O. et al. | 2018
- 1423
-
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trialWirsching, H. G. / Tabatabai, G. / Roelcke, U. / Hottinger, A. F. / Jörger, F. / Schmid, A. / Plasswilm, L. / Schrimpf, D. / Mancao, C. / Capper, D. et al. | 2018
- 1431
-
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological studyGramatzki, D. / Roth, P. / Rushing, E. J. / Weller, J. / Andratschke, N. / Hofer, S. / Korol, D. / Regli, L. / Pangalu, A. / Pless, M. et al. | 2018
- 1437
-
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancerDerosa, L. / Hellmann, M. D. / Spaziano, M. / Halpenny, D. / Fidelle, M. / Rizvi, H. / Long, N. / Plodkowski, A. J. / Arbour, K. C. / Chaft, J. E. et al. | 2018
- 1445
-
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classificationLiu, L. / Toung, J. M. / Jassowicz, A. F. / Vijayaraghavan, R. / Kang, H. / Zhang, R. / Kruglyak, K. M. / Huang, H. J. / Hinoue, T. / Shen, H. et al. | 2018
- 1454
-
Early evolutionary divergence between papillary and anaplastic thyroid cancersCapdevila, J. / Mayor, R. / Mancuso, F. M. / Iglesias, C. / Caratù, G. / Matos, I. / Zafón, C. / Hernando, J. / Petit, A. / Nuciforo, P. et al. | 2018
- 1461
-
Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancerKatakami, N. / Harada, T. / Murata, T. / Shinozaki, K. / Tsutsumi, M. / Yokota, T. / Arai, M. / Tada, Y. / Narabayashi, M. / Boku, N. et al. | 2018
- 1468
-
No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3)Muller, D. C. / Hodge, A. M. / Fanidi, A. / Albanes, D. / Mai, X. M. / Shu, X. O. / Weinstein, S. J. / Larose, T. L. / Zhang, X. / Han, J. et al. | 2018
- 1476
-
Oral bisphosphonate use and lung cancer incidence among postmenopausal womenTao, M. H. / Chen, S. / Freudenheim, J. L. / Cauley, J. A. / Johnson, K. C. / Mai, X. / Sarto, G. E. / Wakelee, H. / Boffetta, P. / Wactawski-Wende, J. et al. | 2018
- 1486
-
Functional immune characterization of HIV-associated non-small-cell lung cancerPinato, D. J. / Kythreotou, A. / Mauri, F. A. / Suardi, E. / Allara, E. / Shiner, R. J. / Akarca, A. U. / Trivedi, P. / Gupta, N. / Dalla Pria, A. et al. | 2018
- 1486
-
The hard road to data interpretation: the road is hard too for the patientGore-Booth, J. et al. | 2018
- 1488
-
Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 geneBrahmi, M. / Alberti, L. / Tirode, F. / Karanian, M. / Eberst, L. / Pissaloux, D. / Cassier, P. / Blay, J. Y. et al. | 2018
- 1490
-
Letter to the editor on ‘Body mass index and 20-specific cancers—re-analyses of dose-response meta-analyses of observational studies’Markozannes, G. / Kalliala, I. / Kyrgiou, M. / Tsilidis, K. K. et al. | 2018
- 1493
-
Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end pointsRoselló, S. / Cervantes, A. et al. | 2018
- 1494
-
New formulation, new drug? The importance of assessing the safety of new supportive care formulations in oncologyJordan, K. et al. | 2018
- 1497
-
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysisPoggio, F. / Bruzzone, M. / Ceppi, M. / Pondé, N. F. / La Valle, G. / Del Mastro, L. / de Azambuja, E. / Lambertini, M. et al. | 2018
- 1509
-
Advances in the systemic treatment of melanoma brain metastasesOliva, I. C. G. / Schvartsman, G. / Tawbi, H. et al. | 2018
- 1521
-
Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trialFokas, E. / Fietkau, R. / Hartmann, A. / Hohenberger, W. / Grützmann, R. / Ghadimi, M. / Liersch, T. / Ströbel, P. / Grabenbauer, G. G. / Graeven, U. et al. | 2018
- 1528
-
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOCremolini, C. / Antoniotti, C. / Lonardi, S. / Bergamo, F. / Cortesi, E. / Tomasello, G. / Moretto, R. / Ronzoni, M. / Racca, P. / Loupakis, F. et al. | 2018
- 1535
-
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapySchwartzberg, L. / Roeland, E. / Andric, Z. / Kowalski, D. / Radic, J. / Voisin, D. / Rizzi, G. / Navari, R. / Gralla, R. J. / Karthaus, M. et al. | 2018
- 1541
-
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerHortobagyi, G. N. / Stemmer, S. M. / Burris, H. A. / Yap, Y. S. / Sonke, G. S. / Paluch-Shimon, S. / Campone, M. / Petrakova, K. / Blackwell, K. L. / Winer, E. P. et al. | 2018
- 1548
-
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancerGerber, D. E. / Horn, L. / Boyer, M. / Sanborn, R. / Natale, R. / Palmero, R. / Bidoli, P. / Bondarenko, I. / Germonpre, P. / Ghizdavescu, D. et al. | 2018
- 1554
-
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC countsLorente, D. / Olmos, D. / Mateo, J. / Dolling, D. / Bianchini, D. / Seed, G. / Flohr, P. / Crespo, M . / Figueiredo, I. / Miranda, S. et al. | 2018
- 1561
-
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumorsFerrarotto, R. / Eckhardt, G. / Patnaik, A. / LoRusso, P. / Faoro, L. / Heymach,. J. V. / Kapoun, A. M. / Xu, L. / Munster, P. et al. | 2018
- 1569
-
Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanomaLewin, J. / Sayers, L. / Kee, D. / Walpole, I. / Sanelli, A. / te Marvelde, L. / Herschtal, A. / Spillane, J. / Gyorki, D. / Speakman, D. et al. | 2018
- 1575
-
T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regressionAndersen, R. / Borch, T. H. / Draghi, A. / Gokuldass, A. / Rana, M. A. H. / Pedersen, M. / Nielsen, M. / Kongsted, p. / Kjeldsen, J. W. / Westergaard, M. C. W. et al. | 2018
- 1582
-
Representation of obese participants in obesity-related cancer randomized trialsPestine, E. / Stokes, A. / Trinquart, L. et al. | 2018
- 1588
-
The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patientsLongué, M. / Cabarrou, B. / Wallet, J. / Brodowicz, T. / Roché, H. / Boher, J. M. / Delord, J. P. / Penel, N. / Filleron, T. et al. | 2018
- 1594
-
Radio-pharmaceuticals for cancer treatment: are they ready for prime time yet?Turck, R. et al. | 2018
- 1598
-
Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cellsCappelletti, V. / Miodini, P. / Reduzzi, C. / Alfieri,. S. / Daidone, M. G. / Licitra, L. / Locati, L. D. et al. | 2018
- 1598
-
HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patientsTan, R. Y. C. / Camat, M. D. / Ng, M. / Lim, T. H. / Lim, A. S. T. / Lim, K. H. / Tan, I. B. H. et al. | 2018
- 1601
-
The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?Trensz, P. / Calvel, l. / Kurtz, J. E. et al. | 2018
- 1602
-
Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanomaSasaki, K. / Uehara, J. / Iinuma, S. / Doi, H. / Honma, M. / Toki, Y. / Ishida-Yamamoto, A. et al. | 2018
- 1604
-
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial populationButi, S. / Puligandla, M. / Bersanelli, M. / DiPaola, R. S. / Manola, J. / Taguchi, S. / Haas, N. B. et al. | 2018
- 1605
-
Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?Hierro, C. / Alsina, M. / Sánchez, M. / Serra, V. / Rodon, J. / Tabernero,. J. et al. | 2018
- 1606
-
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)Dunn, L. A. / Fury, M. G. / Xiao, H. / Baxi, S. S. / Sherman, E. J. / Korte, S. / Pfister, C. / Haque, S. / Katabi, N. / Ho, A. L. et al. | 2018
- 1607
-
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabSwain, S. M. / Schneeweiss, A. / Gianni, L. / Gao, J. J. / Stein, A. / Waldron-Lynch, M. / Heeson, S. / Beattie, M. S. / Yoo, B. / Cortes, J. et al. | 2018
- 1609
-
Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven’t found what we’re looking forRobson, M. et al. | 2018
- 1610
-
HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?Fotopoulou, C. / Sehouli, J. / Mahner, S. / Harter, P. / Van Nieuwenhuysen, E. / Gonzalez-Martin, A. / Vergote, I. / Chiva, L. / Du Bois, A. et al. | 2018
- 1613
-
PARPi related toxicities: do we need more appropriate instruments to evaluate it?Lorusso, D. / Pignata, S. et al. | 2018
- 1616
-
Identifying patients who may benefit from oxaliplatin-containing perioperative chemo(radio)therapy for rectal cancerPapamichael, D. / Glynne-Jones, R. et al. | 2018
- 1618
-
The right chance for temozolomide in metastatic colorectal cancer?Sartore-Bianchi, A. / Siena, S. et al. | 2018
- 1620
-
Now the dust has settled over immune checkpoint blockade in metastatic prostate cancerMehra, N. / Gerritsen, W. et al. | 2018
- 1622
-
Surrogate end points in lymphomaBatlevi, C. L. / Younes, A. et al. | 2018
- 1623
-
The right compound for the right target: tackling RETSeoane, J. / Capdevila, J. et al. | 2018
- 1625
-
Artificial intelligence for melanoma diagnosis: how can we deliver on the promise?Mar, V. J. / Soyer, H. P. et al. | 2018
- 1628
-
Tumor-treating fields: time for demystificationWeller, M. et al. | 2018
- 1630
-
Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumorsSholl, L. M. et al. | 2018
- 1632
-
Prognostic gene expression signatures in sarcoma: finding clarity in complexityCharville, G. W. / Lazar, A. J. et al. | 2018
- 1634
-
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†Cardoso, F. / Senkus, E. / Costa, A. / Papadopoulos, E. / Aapro, M. / André, F. / Harbeck, N. / Aguilar Lopez, B. / Barrios, C. H. / Bergh, J. et al. | 2018
- 1658
-
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-upHonecker, F. / Aparicio, J. / Berney, D. / Beyer, J. / Bokemeyer, C. / Cathomas, R. / Clarke, N. / Cohn-Cedermark, G. / Daugaard, G. / Dieckmann, K. P. et al. | 2018
- 1687
-
ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patientsHutchings, M. / Ladetto, M. / Buske, C. / de Nully Brown, P. / Ferreri, A. J. / Pfreundschuh, M. / Schmitz, N. / Balari, A. S. / van Imhoff, G. / Walewski, J. et al. | 2018
- 1701
-
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerBonomi, P. D. / Gandara, D. / Hirsch, F. R. / Kerr, K. M. / Obasaju, C. / Paz-Ares, L. / Bellomo, C. / Bradley, J. D. / Bunn Jr, P. A. / Culligan, M. et al. | 2018
- 1710
-
Pleural mesothelioma: is the surgeon still there?Opitz, I. / Weder, W. et al. | 2018
- 1718
-
Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guideScotté, F. / Bossi, P. / Carola, E. / Cudennec, T. / Dielenseger, P. / Gomes, F. / Knox, S. / Strasser, F. et al. | 2018
- 1727
-
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?Ochoa de Olza, M. / Oliva, M. / Hierro, C. / Matos, I. / Martin-Liberal, J. / Garralda, E. et al. | 2018
- 1741
-
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancerZhang, J. / Lin, Y. / Sun, X. J. / Wang, B. Y. / Wang, Z. H. / Luo, J. F. / Wang, L. P. / Zhang, S. / Cao, J. / Tao, Z. H. et al. | 2018
- 1748
-
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trialMalorni, L. / Curigliano, G. / Minisini, A. M. / Cinieri, S. / Tondini, C. A. / D’Hollander, K. / Arpino, G. / Bernardo, A. / Martignetti, A. / Criscitiello, C. et al. | 2018
- 1755
-
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trialArnedos, M. / Bayar, M. A. / Cheaib, B. / Scott, V. / Bouakka, I. / Valent, A. / Adam, J. / Leroux-Kozal, V. / Marty, V. / Rapinat, A. et al. | 2018
- 1763
-
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trialYardley, D. A. / Coleman, R. / Conte, P. / Cortes, J. / Brufsky, A. / Shtivelband, M. / Young, R. / Bengala, C. / Ali, H. / Eakel, J. et al. | 2018
- 1771
-
Different menopausal hormone regimens and risk of breast cancerBrusselaers, N. / Tamimi, R. M. / Konings, P. / Rosner, B. / Adami, H. O. / Lagergren, J. et al. | 2018
- 1777
-
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trialIgnatiadis, M. / Litière, S. / Rothe, F. / Riethdorf, S. / Proudhon, C. / Fehm, T. / Aalders, K. / Forstbauer, H. / Fasching, P. A. / Brain, E. et al. | 2018
- 1784
-
Safety and dose modification for patients receiving niraparibBerek, J. S. / Matulonis, U. A. / Peen, U. / Ghatage, P. / Mahner, S. / Redondo, A. / Lesoin, A. / Colombo, N. / Vergote, I. / Rosengarten, O. et al. | 2018
- 1793
-
Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trialHofheinz, R. D. / Arnold, D. / Fokas, E. / Kaufmann, M. / Hothorn, T. / Folprecht, G. / Fietkau, R. / Hohenberger, W. / Ghadimi, M. / Liersch, T. et al. | 2018
- 1800
-
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylationMorano, F. / Corallo, S. / Niger, M. / Barault, L. / Milione, M. / Berenato, R. / Moretto, R. / Randon, G. / Antista, M. / Belfiore, A. et al. | 2018
- 1807
-
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 studyHansen, A. R. / Massard, C. / Ott, P. A. / Haas, N. B. / Lopez, J. S. / Ejadi, S. / Wallmark, J. M. / Keam, B. / Delord, J. P. / Aggarwal, R. et al. | 2018
- 1814
-
Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive diseaseKamoun, A. / Cancel-Tassin, G. / Fromont, G. / Elarouci, N. / Armenoult, L. / Ayadi, M. / Irani, J. / Leroy, X. / Villers, A. / Fournier, G. et al. | 2018
- 1822
-
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trialsMaurer, M. J. / Habermann, T. M. / Shi, Q. / Schmitz, N. / Cunningham, D. / Pfreundschuh, M. / Seymour, J. F. / Jaeger, U. / Haioun, C. / Tilly, H. et al. | 2018
- 1828
-
Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomasLe Guellec, S. / Lesluyes, T. / Sarot, E. / Valle, C. / Filleron, T. / Rochaix, P. / Valentin, T. / Pérot, G. / Coindre, J. M. / Chibon, F. et al. | 2018
- 1836
-
Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologistsHaenssle, H. A. / Fink, C. / Schneiderbauer, R. / Toberer, F. / Buhl, T. / Blum, A. / Kalloo, A. / Hassen, A. B. / Thomas, L. / Enk, A. et al. | 2018
- 1843
-
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialCorrie, P. G. / Marshall, A. / Nathan, P. D. / Lorigan, P. / Gore, M. / Tahir, S. / Faust, G. / Kelly, C. G. / Marples, M. / Danson, S. J. et al. | 2018
- 1853
-
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)Cottrell, T. R. / Thompson, E. D. / Forde, P. M. / Stein, J. E. / Duffield, A. S. / Anagnostou, V. / Rekhtman, N. / Anders, R. A. / Cuda, J. D. / Illei, P. B. et al. | 2018
- 1861
-
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaTetzlaff, M. T. / Messina, J. L. / Stein, J. E. / Xu, X. / Amaria, R. N. / Blank, C. U. / van de Wiel, B. A. / Ferguson, P. M. / Rawson, R. V. / Ross, M. I. et al. | 2018
- 1869
-
Selective RET kinase inhibition for patients with RET-altered cancersSubbiah, V. / Velcheti, V. / Tuch, B. B. / Ebata, K. / Busaidy, N. L. / Cabanillas, M. E. / Wirth, L. J. / Stock, S. / Smith, S. / Lauriault, V. et al. | 2018
- 1877
-
Reporting of HRQoL results from the PALOMA-2 trial: Relevant data are still missingKaiser, T. / Köhler, M. / Wieseler, B. et al. | 2018
- 1878
-
Reply to the letter to the editor ‘Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses’ by Kaiser et al.Rugo, H. S. / Iyer, S. / Huang, C. et al. | 2018
- 1879
-
Reply to the letter to the editor ‘Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer’ by Yang et al.Conteduca, V. / De Giorgi, U. / Lauletta, G. et al. | 2018
- 1879
-
Mediastinal lymph node clearance and anti-PD-1 induction in resected NSCLCManapov, F. / Eze, C. / Käsmann, L. / Dantes, M. / Roengvoraphoj, O. et al. | 2018
- 1880
-
Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitorVerstovsek, S. / Subbiah, V. / Masarova, L. / Yin, C. C. / Tang, G. / Manshouri, T. / Asatiani, E. / Daver, N. G. et al. | 2018
- 1882
-
Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based StudyWästerlid, T. / Biccler, J. L. / Brown, P. N. / Bøgsted, M. / Enblad, G. / Mészáros Jørgensen, J. / Christensen, J. H. / Wahlin, B. E. / Smedby, K. E. / El-Galaly, T. C. et al. | 2018
- 1883
-
Reply to the letter to the editor: ‘The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?’ By P. Trendsz et al.Sobrero, A. / Douillard, J. Y. et al. | 2018
- 1884
-
Anti-EGFR therapy in oesophagogastric cancer: precise but not enoughSalati, M. / Cascinu, S. et al. | 2018
- 1887
-
The legacy of Thomas Tursz: building a leading comprehensive cancer center in EuropeSoria, J. C. / Baselga, J. / Piccart, M. et al. | 2018
- 1889
-
Targeting gamma secretase: has progress moved up a Notch?Ileana Dumbrava, E. E. / Mills, G. B. / Yap, T. A. et al. | 2018
- 1892
-
Hodgkin lymphoma staging 50 years later: no more knives or needles!Gallamini, A. et al. | 2018
- 1893
-
Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC positionCiccolini, J. / Del Re, M. / Danesi, R. / Milano, G. / Schellens, J. H. / Raymond, E. et al. | 2018
- 1895
-
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Mateo, J. / Chakravarty, D. / Dienstmann, R. / Jezdic, S. / Gonzalez-Perez, A. / Lopez-Bigas, N. / Ng, C. K. / Bedard, P. L. / Tortora, G. / Douillard, J. Y. et al. | 2018
- 1903
-
Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF supportLyman, G. H. / Yau, L. / Nakov, R. / Krendyukov, A. et al. | 2018
- 1911
-
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancerMassard, C. / Azaro, A. / Soria, J. C. / Lassen, U. / Le Tourneau, C. / Sarker, D. / Smith, C. / Ohnmacht, U. / Oakley, G. / Patel, B. K. et al. | 2018
- 1918
-
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancerBasu, B. / Krebs, M. G. / Sundar, R. / Wilson, R. H. / Spicer, J. / Jones, R. / Brada, M. / Talbot, D. C. / Steele, N. / Ingles Garces, A. H. et al. | 2018
- 1926
-
Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18Voltin, C. A. / Goergen, H. / Baues, C. / Fuchs, M. / Mettler, J. / Kreissl, S. / Oertl, J. / Klaeser, B. / Moccia, A. / Drzezga, A. et al. | 2018
- 1932
-
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding studyde Vos, S. / Swinnen, L. J. / Wang, D. / Reid, E. / Fowler, N. / Cordero, J. / Dunbar, M. / Enschede, S. H. / Nolan, C. / Petrich, A. M. et al. | 2018
- 1939
-
Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialEttl, J. / Quek, R. G. / Lee, K. H. / Rugo, H. S. / Hurvitz, S. / Gonçalves, A. / Fehrenbacher, L. / Yerushalmi, R. / Mina, L. A. / Martin, M. et al. | 2018
- 1948
-
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumorsDiossy, M. / Reiniger, L. / Sztupinszki, Z. / Krzystanek, M. / Timms, K. M. / Neff, C. / Solimeno, C. / Pruss, D. / Eklund, A. C. / Tóth, E. et al. | 2018
- 1955
-
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled studyVan Cutsem, E. / Yoshino, T. / Lenz, H. J. / Lonardi, S. / Falcone, A. / Limón, M. L. / Saunders, M. / Sobrero, A. / Park, Y. S. / Ferreiro, R. et al. | 2018
- 1964
-
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancerSoria, J. C. / Ho, S. N. / Varella-Garcia, M. / Iafrate, A. J. / Solomon, B. J. / Shaw, A. T. / Blackhall, F. / Mok, T. S. / Wu, Y. L. / Pestova, K. et al. | 2018
- 1972
-
Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 StudyHong, R. L. / Hsiao, C. F. / Ting, L. L. / Ko, J. Y. / Wang, C. W. / Chang, J. T. / Lou, P. J. / Wang, H. M. / Tsai, M. H. / Lai, S. C. et al. | 2018
- 1980
-
Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancerHanna, G. J. / Supplee, J. G. / Kuang, Y. / Mahmood, U. / Lau, C. J. / Haddad, R. I. / Jänne, P. A. / Paweletz, C. P. et al. | 2018
- 1987
-
Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in BelgiumKenis, C. / Decoster, L. / Flamaing, J. / Debruyne, P. R. / De Groof, I. / Focan, C. / Cornélis, F. / Verschaeve, V. / Bachmann, C. / Bron, D. et al. | 2018
- 1995
-
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcomaJones, R. L. / Demetri, G. D. / Schuetze, S. M. / Milhem, M. / Elias, A. / Van Tine, B. A. / Hamm, J. / McCarthy, S. / Wang, G. / Parekh, T. et al. | 2018
- 2003
-
Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patientsSchmidt, L. / Fredsøe, J. / Kristensen, H. / Strand, S. H. / Rasmussen, A. / Høyer, S. / Borre, M. / Mouritzen, P. / Ørntoft, T. / Sørensen, K. D. et al. | 2018
- 2010
-
Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatmentYoon, W. / Yoo, Y. / Chae, Y. S. / Kee, S. H. / Kim, B. M. et al. | 2018
- 2018
-
Reply to the letter to the editor ‘Anti-EGFR therapy in oesophagogastric cancer: precise but not enough’ by M. Salati and S. CascinuRuhstaller, T. / Langer, R. / Thuss-Patience, P. / Eisterer, W. / Stahl, M. et al. | 2018
- 2019
-
Age at diagnosis and prognosis among prostate cancer patients treated with radiotherapy: evidenced from three independent cohort studiesDong, X. / Ma, G. / Chen, F. et al. | 2018
- 2020
-
Reply to the letter to the editor ‘Age at diagnosis and prognosis among prostate cancer patients treated with radiotherapy: evidenced from three independent cohort studies’ by X. Dong, G. Ma and F. ChenPettersson, A. / Robinson, D. / Garmo, H. / Holmberg, L. / Stattin, P. et al. | 2018
- 2021
-
‘Reply to the letter to the editor ‘Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer’ by Yang et al.’ by V. Conteduca, U. De giorgi and G. LaulettaYang, D. D. / Nguyen, P. L. et al. | 2018
- 2022
-
Combining plasma-based biosources to predict treatment response in NSCLC patientsBracht, J. W. / Berenguer, J. / Karachaliou, N. / Filipska, M. / Rosell, R. et al. | 2018
- 2023
-
AJCC eighth edition for soft tissue sarcoma of the extremities and trunkCates, J. M. et al. | 2018
- 2023
-
What type of man against machine?Smith, H. R. et al. | 2018
- 2024
-
Reply to the letter to the editor ‘What type of man against machine?’ by H. SmithHaenssle, H. A. / Fink, C. et al. | 2018
- 2027
-
Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are neededSmyth, E. C. / Cervantes, A. et al. | 2018
- 2028
-
TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancerCosta, D. B. et al. | 2018
- 2030
-
Adjuvant treatment of high-risk renal cell carcinoma: the jury is still outProcopio, G. / Sepe, P. / Verzoni, E. / Pignata, S. / Bamias, A. et al. | 2018
- 2033
-
Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018Stiefel, F. / Kiss, A. / Salmon, P. / Peters, S. / Razavi, D. / Cervantes, A. / Margulies, A. / Bourquin, C. et al. | 2018
- 2037
-
Translational insights into gastrointestinal stromal tumor and current clinical advancesHemming, M. L. / Heinrich, M. C. / Bauer, S. / George, S. et al. | 2018
- 2046
-
Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancersChen, X. / Li, Y. / Ouyang, T. / Li, J. / Wang, T. / Fan, Z. / Fan, T. / Lin, B. / Xie, Y. et al. | 2018
- 2052
-
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300Bang, Y.-J. / Yañez, E. / Van Cutsem, R. E. / Lee, K.-W. / Wyrwicz, L. / Schenker, M. / Alsina, M. / Ryu, M.-H. / Chung, H.-C. / Evesque, L. et al. | 2018
- 2061
-
Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2Chang, K. / Willis, A. A. / Reumers, J. / Taggart, M. W. / San, F. A. / Thirumurthi, L. S. / Kanth, P. / Delker, D. A. / Hagedorn, C. H. / Lynch, P. M. et al. | 2018
- 2068
-
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerKron, A. / Alidousty, C. / Scheffler, M. / Merkelbach-Bruse, S. / Seidel, D. / Riedel, R. / Ihle, M. A. / Michels, S. / Nogova, L. / Fassunke, J. et al. | 2018
- 2076
-
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE studyThomas, M. / Ponce-Aix, S. / Navarro, A. / Riera-Knorrenschild, J. / Schmidt, M. / Wiegert, E. / Kapp, K. / Wittig, B. / Mauri, C. / Gómez, M. D. et al. | 2018
- 2085
-
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersSabari, J. K. / Leonardi, G. C. / Shu, C. A. / Umeton, R. / Montecalvo, J. / Ni, A. / Chen, R. / Dienstag, J. / Mrad, C. / Bergagnini, I. et al. | 2018
- 2092
-
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertionsPiotrowska, Z. / Costa, D. B. / Oxnard, G. R. / Huberman, M. / Gainor, J. F. / Lennes, I. T. / Muzikansky, A. / Shaw, A. T. / Azzoli, C. G. / Heist, R. S. et al. | 2018
- 2098
-
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trialStaehler, M. / Motzer, R. J. / George, D. J. / Pandha, H. S. / Donskov, F. / Escudier, B. / Pantuck, A. J. / Patel, A. / DeAnnuntis, L. / Bhattacharyya, H. et al. | 2018
- 2105
-
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-IIDietz, A. / Wichmann, G. / Kuhnt, T. / Pfreundner, L. / Hagen, R. / Scheich, M. / Kölbl, O. / Hautmann, M. G. / Strutz, J. / Schreiber, F. et al. | 2018
- 2115
-
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanomaTan, A. C. / Emmett, L. / Lo, S. / Liu, V. / Kapoor, R. / Carlino, M. S. / Guminski, A. D. / Long, G. V. / Menzies, A. M. et al. | 2018
- 2121
-
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer typesParé, L. / Pascual, T. / Seguí, E. / Teixidó, C. / Gonzalez-Cao, M. / Galván, P. / Rodríguez, A. / González, B. / Cuatrecasas, M. / Pineda, E. et al. | 2018
- 2129
-
Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publicationLiang, F. / Zhu, J. / Mo, M. / Zhou, C. M. / Jia, H. X. / Xie, L. / Zheng, Y. / Zhang, S. et al. | 2018
- 2135
-
‘Optimism bias’ in contemporary national clinical trial network phase III trials: are we improving?Zakeri, K. / Noticewala, S. S. / Vitzthum, L. K. / Sojourner, E. / Shen, H. / Mell, L. K. et al. | 2018
- 2140
-
Response to ‘The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’Ogale, S. et al. | 2018
- 2141
-
Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infectionScully, E. P. / Rutishauser, R. L. / Simoneau, C. R. / Delagrèverie, H. / Euler, Z. / Thanh, C. / Li, J. Z. / Hartig, H. / Bakkour, S. / Busch, M. et al. | 2018
- 2143
-
Toxicity of oxaliplatin rechallenge in metastatic colorectal cancerMauri, G. / Bencardino, K. / Sartore-Bianchi, A. / Siena, S. et al. | 2018
- 2144
-
Prognostic utility of HPV specific testing in addition to p16 immunohistochemistry in oropharyngeal squamous cell carcinomaSathasivam, H. P. / Santambrogio, A. / Andoniadou, C. L. / Robinson, M. / Thavaraj, S. et al. | 2018
- 2145
-
Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitorKunimasa, K. / Nakamura, H. / Sakai, K. / Kimura, M. / Inoue, T. / Tamiya, M. / Nishino, K. / Kumagai, T. / Nakatsuka, S. / Endo, H. et al. | 2018
- 2147
-
Small repeated boluses are unreliable to provide rapid analgesia with intravenous morphine titration and mislead conversion ratio to oral morphineMercadente, S. et al. | 2018
- 2148
-
Reply to the letter to the editor ‘Small repeated boluses are unreliable to provide rapid analgesia with intravenous morphine titration and mislead conversion ratio to oral morphine’ by Mercadante S.Fallon, M. / Ripamonti, C. I. et al. | 2018
- 2150
-
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) TrialTan, W. W. / Hillman, D. W. / Salim, M. / Northfelt, D. W. / Anderson, D. M. / Stella, P. J. / Niedringhaus, R. / Bernath, A. M. / Gamini, S. S. / Palmieri, F. et al. | 2018
- 2151
-
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabLoibl, S. / Majewski, I. / Guarneri, V. / Nekljudova, V. / Holmes, E. / Bria, E. / Denkert, C. / Schem, C. / Sotiriou, C. / Loi, S. et al. | 2018
- 2152
-
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialShi, W. / Jiang, T. / Nuciforo, P. / Hatzis, C. / Holmes, E. / Harbeck, N. / Sotiriou, C. / Peña, L. / Loi, S. / Rosa, D. D. et al. | 2018
- 2153
-
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Curigliano, G. / Burstein, H. J. / Winer, E. P. / Gnant, M. / Dubsky, P. / Loibl, S. / Colleoni, M. / Regan, M. M. / Piccart-Gebhart, M. / Senn, H.-J. et al. | 2018
- 2155
-
Developing prognostic models for advanced prostate cancer when the goal line keeps changingFu, S. Y. F. / Chi, K. N. et al. | 2018
- 2157
-
How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studiesAscierto, P A / Marabelle, A et al. | 2018
- 2160
-
Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?Thai, A. A. / Solomon, B. J. et al. | 2018
- 2163
-
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)Marabelle, A / Andtbacka, R / Harrington, K / Melero, I / Leidner, R / de Baere, T / Robert, C / Ascierto, P A / Baurain, J -F / Imperiale, M et al. | 2018
- 2175
-
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesSmoragiewicz, M. / Bogaerts, J. / Calvo, E. / Marabelle, A. / Perrone, A. / Seymour, L. / Shalabi, A. / Siu, L. L. / Tabernero, J. / Giaccone, G. et al. | 2018
- 2182
-
Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeuticsNikanjam, M. / Cohen, P. R. / Kato, S. / Sicklick, J. K. / Kurzrock, R. et al. | 2018
- 2183
-
Human endogenous retroviruses and their implication for immunotherapeutics of cancerAttermann, A S / Bjerregaard, A -M / Saini, S K / Grønbæk, K / Hadrup, S R et al. | 2018
- 2200
-
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancerArmstrong, A J / Lin, P / Higano, C S / Sternberg, C N / Sonpavde, G / Tombal, B / Templeton, A J / Fizazi, K / Phung, D / Wong, E K et al. | 2018
- 2208
-
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancerLong, G. V. / Tykodi, S. S. / Schneider, J. G. / Garbe, C. / Gravis, G. / Rashford, M. / Agrawal, S. / Grigoryeva, E. / Bello, A. / Roy, A. et al. | 2018
- 2214
-
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX studyGadgeel, S. / Peters, S. / Mok, T. / Shaw, a. T. / Kim, D. W. / Ou, S. I. / Pérol, M. / Wrona, A. / Novello, S. / Rosell, R. et al. | 2018
- 2223
-
Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancersGłodzik, D / Purdie, C / Rye, I H / Simpson, P T / Staaf, J / Span, P N / Russnes, H G / Nik-Zainal, S et al. | 2018
- 2232
-
Immunological differences between primary and metastatic breast cancerSzekely, B. / Bossuyt, V. / Li, X. / Wali, V. B. / Patwardhan, G. A. / Frederick, C. / Silber, A. / Park, T. / Harigopal, M. / Pelekanou, V. et al. | 2018
- 2240
-
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trialMooi, J K / Wirapati, P / Asher, R / Lee, C K / Savas, P / Price, T J / Townsend, A / Hardingham, J / Buchanan, D / Williams, D et al. | 2018
- 2247
-
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trialColevas, A D / Bahleda, R / Braiteh, F / Balmanoukian, A / Brana, I / Chau, N G / Sarkar, I / Molinero, L / Grossman, W / Kabbinavar, F et al. | 2018
- 2254
-
Oncogenes expand during evolution to withstand somatic amplificationWang, X. / Li, X. / Zhang, L. / Wong, S. H. / Wang, M. H. T. / Tse, G. / Dai, R. Z. W. / Nakatsu, G. / Coker, O. O. / Chen, Z. et al. | 2018
- 2261
-
Neoadjuvant rectal score: run with the hare and hunt with the houndsSclafani, F. / Kalaitzaki, E. / Cunningham, D. / Tait, D. / Brown, G. / Chau. I. et al. | 2018
- 2262
-
Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancerTaniguchi, Y / Takeda, M / Tamiya, A / Kasai, T / Atagi, S et al. | 2018
- 2263
-
A centralised multidisciplinary clinic approach for germ cell tumoursCrawford, S M et al. | 2018
- 2264
-
Reply to the letter to the editor 'A centralised multidisciplinary clinic approach for germ cell tumours' by CrawfordAlbany, C / Adra, N / Snavely, A / Cary, C / Masterson, T / Foster, R / Kesler, K / Ulbright, T / Cheng, L / Chovanec, M et al. | 2018
- 2265
-
Reply to the letter to the editor 'Body mass index and 20-specific cancers—re-analyses of dose–response meta-analyses of observational studies' by Markozannes et al.Choi, E K / Eisenhut, M / van der Vliet, H J / Lee, K H / Shin, J I et al. | 2018
- 2266
-
ESCAT: a step in the right directionSilver, A J / Warner, J L et al. | 2018
- 2268
-
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principleMattos-Arruda, L De / Weigelt, B / Cortes, J / Won, H H / Ng, C K Y / Nuciforo, P / Bidard, F -C / Aura, C / Saura, C / Peg, V et al. | 2018
- 2269
-
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCCKnox, J J / Barrios, C H / Kim, T M / Cosgriff, T / Srimuninnimit, V / Pittman, K / Sabbatini, R / Rha, S Y / Flaig, T W / Page, R D et al. | 2018
- 2271
-
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessCzuczman, M S / Leonard, J P / Jung, S / Johnson, J L / Hsi, E D / Byrd, J C / Cheson, B D et al. | 2018
- 2273
-
Duration of adjuvant trastuzumab: might less be more?Filho, O. M. / Burstein, H. J. et al. | 2018
- 2274
-
CDK4/6 inhibitors as neoadjuvant treatment in breast cancer—what can we learn?Brandão, M. / Ignatiadis, M. et al. | 2018
- 2278
-
Carboplatin in the neoadjuvant treatment of triple-negative breast cancer—ready for prime time?Foukakis, T. et al. | 2018
- 2280
-
KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancerMontagut, C. / Vidal, J. / Visa, L. et al. | 2018
- 2282
-
Towards risk-adapted perioperative treatment of gastroesophageal cancerLordick, F. et al. | 2018
- 2284
-
More accurate prognostic prediction in diffuse large B-cell lymphoma: beyond cell-of-originKoya, J. / Kataoka, K. et al. | 2018
- 2286
-
Quality of life assessment using patient-reported outcome (PRO) measures: still a Cinderella outcome?Fallowfield, L. J. et al. | 2018
- 2288
-
Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016Marandino, L. / La Salvia, A. / Sonetto, C. / De Luca, E. / Pignataro, D. / Zichi, C. / Di Stefano, R. F. / Ghisoni, E. / Lombardi, P. / Mariniello, A. et al. | 2018
- 2296
-
Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib studyHobbs, B. P. / Kane, M. J. / Hong, D. S. / Landin, R. et al. | 2018
- 2302
-
Novel therapies in urothelial carcinoma: a biomarker-driven approachIyer, G. / Rosenberg, J. E. et al. | 2018
- 2313
-
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approachGalot, R. / Le Tourneau, C. / Guigay, J. / Licitra, L. / Tinhofer, I. / Kong, A. / Caballero, C. / Fortpied, C. / Bogaerts, J. / Govaerts, A.-S. et al. | 2018
- 2328
-
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER studyConte, P. / Frassoldati, A. / Bisagni, G. / Brandes, A. A. / Donadio, M. / Garrone, O. / Piacentini, F. / Cavanna, L. / Giotta, F. / Aieta, M. et al. | 2018
- 2334
-
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancerCottu, P. / D'Hondt, V. / Dureau, S. / Lerebours, F. / Desmoulins, I. / Heudel, P.-E. / Duhoux, F. P. / Levy, C. / Mouret-Reynier, M.-A. / Dalenc, F. et al. | 2018
- 2341
-
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixtoLoibl, S. / Weber, K. E. / Timms, K. M. / Elkin, E. P. / Hahnen, E. / Fasching, P. A. / Lederer, B. / Denkert, C. / Schneeweiss, A. / Braun, S. et al. | 2018
- 2348
-
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancerKruger, S. / Heinemann, V. / Ross, C. / Diehl, F. / Nagel, D. / Ormanns, S. / Liebmann, S. / Prinz-Bravin, I. / Westphalen, C. B. / Haas, M. et al. | 2018
- 2356
-
A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trialSmyth, E. C. / Nyamundanda, G. / Cunningham, D. / Fontana, E. / Ragulan, C. / Tan, I. B. / Lin, S. J. / Wotherspoon, A. / Nankivell, M. / Fassan, M. et al. | 2018
- 2363
-
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissueCiavarella, S. / Vegliante, M. C. / Fabbri, M. / De Summa, S. / Melle, F. / Motta, G. / De Iuliis, V. / Opinto, G. / Enjuanes, A. / Rega, S. et al. | 2018
- 2371
-
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trialGross-Goupil, M. / Kwon, T. G. / Eto, M. / Ye, D. / Miyake, H. Seo, S. I. / Byun, S.-S. / Lee, J. L. / Master, V. / Jin, J. et al. | 2018
- 2379
-
Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancerWan, Y. / Liu, B. / Lei, H. / Zhang, B. / Wang, Y. / Huang, H. / Chen, S. / Feng, Y. / Zhu, L. / Gu, Y. et al. | 2018
- 2384
-
A comparison of matched interim analysis publications and final analysis publications in oncology clinical trialsWayant, C. / Vassar, M. et al. | 2018
- 2391
-
Can estrogen receptor status predict for shorter duration of adjuvant trastuzumab in early-stage breast cancer?Mathew, A. / Erqou, S. et al. | 2018
- 2392
-
Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencingZhu, Y. C. / Wang, W. X. / Xu, C. W. / Zhang, Q. X. / Du, K. Q. / Chen, G. / Lv, T. F. / Song, Y. et al. | 2018
- 2393
-
Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trialGaiser, M. R. / Lorenzen, S. / Merx, K. / Trojan, J. / Ocvirk, J. / Ettrich, T. J. / Al-Batran, S.-E. / Schulz, H. / Homann, N. / Feustel, H.-P. et al. | 2018
- 2395
-
Comment on ‘Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy’Brentisci, C. / Gangemi, M. / Migliore, E. / Mirabelli, D. / Stura, A. et al. | 2018
- 2396
-
Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trialsSen, S. / Pestana, R. C. / Hess, K. / Viola, G. M. / Subbiah, V. et al. | 2018
- i1
-
Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 yearsVansteenkiste, J. / Wauters, E. et al. | 2018
- i3
-
Overview of current systemic management of EGFR-mutant NSCLCHsu, W. H. / Yang, J. C. / Mok, T. S. / Loong, H. H. et al. | 2018
- i10
-
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitorsWestover, D. / Zugazagoitia, J. / Cho, B. C. / Lovly, C. M. / Paz-Ares, L. et al. | 2018
- i20
-
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patientsRemon, J. / Steuer, C. E. / Ramalingam, S. S. / Felip, E. et al. | 2018
- i28
-
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancerRicordel, C. / Friboulet, L. / Facchinetti, F. / Soria, J. C. et al. | 2018
- i38
-
Are liquid biopsies a surrogate for tissue EGFR testing?Goldman, J. W. / Noor, Z. S. / Remon, J. / Besse, B. / Rosenfeld, N. et al. | 2018
- iv1
-
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†Ray-Coquard, I. / Morice, P. / Lorusso, D. / Prat, J. / Oaknin, A. / Pautier, P. / Colombo, N. et al. | 2018
- iv19
-
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†Eichenauer, D A / Aleman, B M P / André, M / Federico, M / Hutchings, M / Illidge, T / Engert, A / Ladetto, M et al. | 2018
- iv30
-
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†Willemze, R. / Hodak, E. / Zinzani, P. L. / Specht, L. / Ladetto, M. et al. | 2018
- iv41
-
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†Kastritis, E / Leblond, V / Dimopoulos, M A / Kimby, E / Staber, P / Kersten, M J / Tedeschi, A / Buske, C et al. | 2018
- iv51
-
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†Casali, P. G. / Abecassis, N. / Bauer, S. / Biagini, R. / Bielack, S. / Bonvalot, S. / Boukovinas, I. / Bovee, J. V. / Brodowicz, T. / Broto, J. M. et al. | 2018
- iv68
-
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†Casali, P. G. / Abecassis, N. / Bauer, S. / Biagini, R. / Bielack, S. / Bonvalot, S. / Boukovinas, I. / Bovee, J. V. / Brodowicz, T. / Broto, J. M. et al. | 2018
- iv79
-
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†Casali, P. G. / Bielack, S. / Abecassis, N. / Aro, H. T. / Bauer, S. / Biagini, R. / Bonvalot, S. / Boukovinas, I. / Bovee, J. V. / Brennan, B. et al. | 2018
- iv96
-
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines†Aapro, M / Beguin, Y / Bokemeyer, C / Dicato, M / Gascón, P / Glaspy, J / Hofmann, A / Link, H / Littlewood, T / Ludwig, H et al. | 2018
- iv111
-
Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines†Larkin, P. J. / Cherny, N. I. / La Carpia, D. / Guglielmo, M. / Ostgathe, C. / Scotté, F. / Ripamonti, C. I. et al. | 2018
- iv126
-
Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines†Bossi, P. / Antonuzzo, A. / Cherny, N. I. / Rosengarten, O. / Pernot, S. / Trippa, F. / Schuler, U. / Snegovoy, A. / Jordan, K. / Ripamonti, C. I. et al. | 2018
- iv143
-
Delirium in adult cancer patients: ESMO Clinical Practice Guidelines†Bush, S. H. / Lawlor, P. G. / Ryan, K. / Centeno, C. / Lucchesi, M. / Kanji, S. / Siddiqi, N. / Morandi, A. / Davis, D. H. / Laurent, M. et al. | 2018
- iv166
-
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines†Fallon, M. / Giusti, R. / Aielli, F. / Hoskin, P. / Rolke, R. / Sharma, M. / Ripamonti, C. I. et al. | 2018
- iv192
-
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†Planchard, D. / Popat, S. / Kerr, K. / Novello, S. / Smit, E. F. / Faivre-Finn, C. / Mok, T. S. / Reck, M. / Van Schil, P. E. / Hellmann, M. D. et al. | 2018